scholarly journals NOB1 Assumes Signifying Capacity in Lung Cancer Diagnosis.

2020 ◽  
Author(s):  
Jun Yang ◽  
Hua Zhong ◽  
Qinghui Yang ◽  
Jian Yu ◽  
Cailing Jin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Roc Curve ◽  
Diagnostic Value ◽  
Pcr Analysis ◽  
Healthy Controls ◽  
Operating Characteristics ◽  
Chi Square ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Abstract Background: NIN1/RPN12 binding protein 1 homolog (NOB1) gene was reported to play a key role in the oncogenesis and prognosis of carcinomas. The aim of the present study was to investigate the expression of NOB1 and its clinical significance in lung cancer, and further explore the diagnostic value of NOB1 in lung cancer patients.Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was used to characterize the expression of NOB1 in 97 lung cancer patients and 55 healthy controls. The associations of NOB1 mRNA expression with clinicopathological factors of lung cancer patients were analyzed by Chi-square test. The receiver operating characteristics (ROC) curve was used to evaluate the diagnostic value of NOB1 in lung cancer.Results: The expression levels of NOB1 mRNA in lung cancer samples were significantly up-regulated compared with healthy controls (P<0.001). And the NOB1 expression was significant correlated with differentiation (P=0.005) and invasion depth (P=0.008). No associations were found between NOB1 expression and other factors (All P>0.05). ROC curve revealed that the area under ROC curve (AUC) was 0.885, with a sensitivity of 76.3% and a specificity of 89.1%. And the cutoff value of NOB1 was 2.225.Conclusion: NOB1 is a sensitive and specific diagnostic marker for lung cancer, and provide a new therapeutic target for lung cancer treatment.

scholarly journals CHD5 may be a promising novel bio-marker for the diagnosis of lung cancer patients

2020 ◽  
Author(s):  
Jun Yang ◽  
Hua Zhong ◽  
Qinghui Yang ◽  
Jian Yu ◽  
Cailing Jin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Roc Curve ◽  
Diagnostic Value ◽  
Suppressor Gene ◽  
Smoking History ◽  
Healthy Controls ◽  
Serum Samples ◽  
Lung Cancer Patients ◽  
Diagnosis Of Lung Cancer

Abstract Background Chromodomain helicase DNA binding protein 5 (CHD5) is a new tumor suppressor gene in various types of cancer. And it is still not clear about the role of CHD5 in lung cancer. In this study, we aim to assess diagnostic value of CHD5 in patients with lung cancer. Methods CHD5 expression in 108 lung cancer serum samples and 65 healthy controls were determined by quantitative Real-Time PCR (qRT-PCR). A receiver operating characteristic (ROC) curve was established to analyze the effect of CHD5 in the diagnosis of lung cancer. Results The expression of CHD5 was significantly decreased in lung cancer samples compared with the healthy controls (P < 0.0001). Advanced TNM stage (P = 0.020), gender (P = 0.001) and smoking history (P = 0.000) were associated with the decreased CHD5 expression. Besides, the results of ROC analysis showed that the area under ROC curve (AUC) was 0.855 with a sensitivity of 87.1% and a specificity of 81.3%. Conclusions In conclusion, this study suggested that CHD5 expression is down-regulated in lung cancer. Furthermore, CHD5 expression could be a potential diagnosis bio-marker in lung cancer patients.

scholarly journals Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer

PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e11528
Author(s):  
Wen-Jun Zhu ◽  
Bo-Jiang Chen ◽  
Ying-Ying Zhu ◽  
Ling Sun ◽  
Yu-Chen Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Roc Curve ◽  
Lung Diseases ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Background MicroRNA-30a (miRNA-30a) levels have been shown to increase in the plasma of lung cancer patients. Herein, we evaluated the miRNA-30a levels in the bronchoalveolar lavage fluid (BALF) of lung cancer patients as a potential biomarker for lung cancer diagnosis. Methods BALF miRNA-30a expression of 174 subjects was quantified using quantitative real-time reverse transcription-polymerase chain reaction and compared between lung cancer patients and control patients with benign lung diseases. Moreover, its diagnostic value was evaluated by performing receiver operating characteristic (ROC) curve analysis. Results The relative BALF miRNA-30a expression was significantly higher in the lung cancer patients than in the controls (0.74 ±  0.55 versus 0.07 ±  0.48, respectively, p < 0.001) as well as in lung cancer patients with stage I–IIA disease than in those with stage IIB–IV disease (0.98 ±  0.64 versus 0.66 ±  0.54, respectively, p < 0.05). Additionally, miRNA-30a distinguished benign lung diseases from lung cancers, with an area under the ROC curve (AUC) of 0.822. ROC analysis also revealed an AUC of 0.875 for the Youden index-based optimal cut-off points for stage I–IIA adenocarcinoma. Thus, increased miRNA-30a levels in BALF may be a useful biomarker for non-small-cell lung cancer diagnosis.

Concentration and integrity indexes of urine cell-free DNA as promising biomarkers for early lung cancer diagnosis

2021 ◽  
Vol 18 (2) ◽  
pp. 129-139
Author(s):  
Sai Ren ◽  
Xiaodong Ren ◽  
Haiqin Guo ◽  
Lan Liang ◽  
Kun Wei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Characteristic Curve ◽  
Healthy Controls ◽  
Cell Free Dna ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Free Dna ◽  
Pcr Targeting

Aim: To explore the role of urine cell-free DNA (ucfDNA) concentration and integrity indexes as potential biomarkers for lung cancer diagnosis. Materials & methods: Quantitative real-time PCR targeting Arthrobacter luteus ( ALU) repeats at three size fragments ( ALU-60, 115 and 247 bp) was performed in 55 lung cancer patients and 35 healthy individuals. Results: ucfDNA concentration and integrity indexes were significantly higher in lung cancer patients than in healthy controls. The area under the receiver operating characteristic curve for differentiating patients with stage I/II from healthy controls by ALU fragments concentration were 0.856, 0.909 and 0.932, respectively. In addition, the ucfDNA integrity indexes in patients with lymph node metastasis were significantly higher than in patients with non-metastatic. Conclusion: ucfDNA concentration and integrity indexes could serve as promising biomarkers for lung cancer diagnosis.

scholarly journals MicroRNA-449a Plays an Indicative Role in Diagnosing Lung Cancer

2020 ◽  
Author(s):  
Jun Yang ◽  
Hua Zhong ◽  
Qinghui Yang ◽  
Jian Yu ◽  
Cailing Jin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Roc Curve ◽  
Diagnostic Value ◽  
Smoking History ◽  
Lung Cancer Patients ◽  
Incidence And Mortality ◽  
Common Causes ◽  
Healthy Control ◽  
The Relationship

Abstract Background: Lung cancer is one of the most common causes of cancer death among all the malignancies worldwide. Evidences suggest that the incidence and mortality of lung cancer has been on the rise. MicroRNA-449a (miR-449a) as one important member of microRNAs, has been demonstrated acting as a tumor suppressor in lung cancer. In this study, we sought to assess the relationship between miR-449a expression level and diagnostic value of lung cancer.Methods: In this present research, quantitative Real-Time PCR was applied to detect the miR-449a expression in 116 lung cancer patients and 41 healthy volunteers. The diagnostic value of miR-449a in lung cancer patients was determined by receiver operating characteristic (ROC) curve.Results: MiR-449a was significantly down-regulated in lung cancer patients compared with healthy control (P<0.05). In addition, miR-449a expression was associated with sex (P=0.004), tumor size (P=0.000), TNM stage (P=0.006) and metastasis (P=0.036). However, there was no correlation with age, smoking history and histological type of lung cancer patients (all P＞0.05). In the ROC analysis, the results showed that the area under the ROC curve (AUC) was 0.902 with the sensitivity of 94.8% and specificity of 78.0%, and the optimum cutoff value was 2.255.Conclusion: MiR-449a expression was down-regulated in lung cancer patients, and it could be an efficient diagnostic biomarker in lung cancer patients.

Detection of FHIT and p16 mRNA Deletion in Biopsy Specimens Obtained by Bronchoscopy for the Diagnosis of Lung Cancer

2013 ◽  
Vol 28 (3) ◽  
pp. 259-266 ◽  
Author(s):  
Ping Chen ◽  
Jian Li ◽  
Yi Wang ◽  
Li-Rong Zhu ◽  
Yi-Ming Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Smoking Status ◽  
Diagnostic Value ◽  
Gene Transcript ◽  
Detection Rates ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

The purpose of this study was to investigate the diagnostic value of the deletion of fragile histidine triad (FHIT) and p16INK4a (p16) mRNA in biopsies obtained by bronchoscopy. Biopsies were analyzed using RT-PCR in 52 patients with lung cancer and 19 patients with benign lung disease. The results showed that the detection rates of FHIT and p16 gene transcript deletion were significantly higher in lung cancer patients than in patients with benign lung disease (65.4% versus 10.5%, p=0.001 and 59.6% versus 5.3%, p<0.001, respectively). The sensitivities for detecting FHIT and p16 transcript deletion in biopsies were 65.4% and 59.6% (combined 80.8%), respectively, which were markedly better than those of histology and cytology (42.3% and 34.6%, respectively; combined 57.7%). In 22 lung cancer patients with negative histology and cytology at initial bronchoscopy, FHIT and p16 mRNA loss was detected in 40.9% (9/22) and 36.4% (8/22) cases, respectively. FHIT mRNA loss was associated with smoking status in lung cancer patients. In conclusion, deletion of FHIT and p16 mRNA can be identified in biopsies obtained during bronchoscopic procedures. FHIT and p16 mRNA deletion can be used as biomarkers in the clinical diagnosis of lung cancer and may serve as adjuncts to histology and cytology in lung cancer diagnosis.

LncRNA CASC2 Plays an Indicative Role in Diagnosing Bladder Cancer

2020 ◽  
Author(s):  
Hao Zi ◽  
Wen-Lin Tao ◽  
Lei Gao ◽  
Zhao-Hua Yu ◽  
Xiao-Dong Bai ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Roc Curve ◽  
Histological Grade ◽  
Diagnostic Value ◽  
Expression Level ◽  
Chi Square ◽  
Healthy Group ◽  
Cancer Group ◽  
Incidence And Mortality

Abstract Background: Bladder cancer is a common cancer of urinary system, with high incidence and mortality. LncRNA CASC2 as a tumor suppressor has been reported to be involved in many human tumors. In this study, we aimed to explore the diagnostic value of CASC2 for bladder cancer patients.Methods: qRT-PCR was used to detect the expression level of CASC2 in 140 bladder cancer patients and 90 healthy volunteers. The differences of CASC2 expression between the cancer group and healthy group were analyzed using student’s t test. The correlation of CASC2 expression with clinical characteristics of the bladder cancer patients was estimated with Chi-square test. In addition, ROC curve was plotted to evaluate the diagnostic value of CASC2 for bladder cancer patients.Results: Serum CASC2 level was lower in bladder cancer patients than that in healthy group (P<0.05). The expression level of CASC2 was significantly associated with histological grade (P=0.000), TNM stage (P=0.000), and lymph node metastasis (P=0.001). The area under the ROC curve (AUC) was 0.864 and the optimal cutoff value was 0.955, suggesting the diagnostic value of CASC2 for bladder cancer. The diagnostic sensitivity was 77.8% and specificity was 85.7%.Conclusion: CASC2 may be a novel biomarker for early diagnosis of bladder cancer.

scholarly journals The lived experiences of smokers with lung cancer

2018 ◽  
Vol 8 (11) ◽  
pp. 75
Author(s):  
Sakina Badiallah Abulqassemi Kashkoei ◽  
Jessie Johnson ◽  
Janet Rankin ◽  
Robert Johnson
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Lived Experiences ◽  
Descriptive Phenomenology ◽  
Lung Cancer Patients ◽  
Self Blame ◽  
Lung Cancer Diagnosis ◽  
Nurses And Physicians ◽  
Insight Into ◽  
Smoke Tobacco

Objective: The aims of this research were to learn about the lived experiences of patients with lung cancer who smoke tobacco and to provide nurses with more insights into complexities of people’s relationship with their smoking.Methods: Descriptive phenomenology was used to explore the lived experiences of smokers with lung cancer. An in-depth unstructured conversational style interview was used as a method for data collection. The study was conducted in the inpatient, outpatient, and day care units at the National Center for Cancer Care and Research (NCCCR) in Qatar. Purposive sampling was used to recruit five lung cancer patients who smoke. Colaizzi’s (1978) method was used to analyze data.Results: Participants described three related themes: (a) fate, (b) a socially acceptable addiction, and (c) self-blame and guilt.Conclusions: The findings of this study are of interest to nurses and physicians who work with lung cancer patients. The findings provide insight into experiences of patients who continue to smoke after their lung cancer diagnosis. Nurses within the smoking cessation clinic will also benefit from patients’ descriptions of what they consider useful and supportive in regards to an empathetic, coaching response to their relationships with tobacco. Future study is needed to elucidate nurses' perception on lung cancer patients who continue to smoke.

scholarly journals Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer

2018 ◽  
Vol 44 (1) ◽  
pp. 18-23 ◽  
Author(s):  
Lihong Zhang ◽  
Hongbin Wang ◽  
Xuejun Dong
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Smoking History ◽  
Lung Cancer Patients ◽  
Pathological Classification ◽  
Cancer Tissues ◽  
Antibody Levels

ABSTRACT Objective: To investigate the diagnostic value of α-enolase (ENO1) and serum ENO1 autoantibody levels in lung cancer. Methods: Immunohistochemistry staining and ELISA were performed to detect ENO1 expression in lung tissue and serum ENO1 autoantibody levels, respectively. Results: The expression of ENO1 was higher in lung cancer tissues than in benign lung disease tissues (p < 0.001). The proportion of lung cancer samples expressing ENO1 was not significantly different among the various pathological classification groups. The proportion of samples expressing ENO1 was higher in lung cancer patients in stages I/II than in those in stages III/IV (χ2 = 5.445; p = 0.018). The expression of ENO1 in lung cancer tissues was not associated with age, gender, or smoking history. Serum ENO1 antibody levels were significantly higher in the lung cancer group than in the benign lung disease and control groups (p < 0.001). The differences among the pathological classification groups were not statistically significant. Serum ENO1 antibody levels were also in lung cancer patients in stages I/II than in those in stages III/IV (p < 0.01). Serum ENO1 antibody levels were not associated with age, gender, or smoking history in lung cancer patients. The ROC curve representing the diagnosis of lung cancer based on ENO1 antibody levels had an area under the curve of 0.806. Conclusions: Our results suggest that high levels of ENO1 are associated with the clinical stage of lung cancer and that ENO1 expression and its serum autoantibody levels show diagnostic value in lung cancer.

Sign in / Sign up

Export Citation Format

Share Document